Intellia Therapeutics, Inc. (NTLA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$134.7M
Cash & Equivalents
$117.4M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$1,986M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06634420 | HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) | PHASE3 | Active Not Recruiting | 80 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-15 | 8-K | Intellia Therapeutics, Inc. (NTLA) (CIK 0001652130) - EX-99.1 | EDGAR |